Render Target: STATIC
Render Timestamp: 2024-11-12T10:44:08.202Z
Commit: 3c1f305a63297e594ac8d7bb5424007d592d68be
XML generation date: 2024-09-20 06:23:33.073
Product last modified at: 2024-05-30T07:11:57.774Z
1% for the planet logo
PDP - Template Name: Chemical Modulators
PDP - Template ID: *******c501c72

Pepstatin A #98806

    Product Information

    Product Usage Information

    Pepstatin A is supplied as a lyophilized powder. For a 10 mM stock, reconstitute 5 mg of powder in 0.73 mL of DMSO. Working concentrations and length of treatment can vary depending on the desired effect.

    Storage

    Store lyophilized at -20ºC, desiccated. In lyophilized form, the chemical is stable for 24 months. Once in solution, store at -20ºC and use within 2 months to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

    Product Description

    Molecular Weight 685.9 g/mol
    Purity >98%
    Molecular Formula C34H63N5O9
    CAS 26305-03-3
    Solubility Soluble in DMSO at 5 mg/mL or ethanol at 1 mg/mL.

    Background

    Pepstatin A is a low molecular weight inhibitor of aspartyl proteases, including pepsin, renin, cathepsin D and cathepsin E (1). Cathepsin D is a ubiquitously expressed lysosomal aspartyl protease involved in the normal degradation of proteins; dysregulation of cathepsin D plays a role in neuronal degradation and malignant transformation. Cathespin D is highly expressed in triple-negative breast cancer (TNBC) cells. Pepstatin A treatment induced apoptosis and autophagy while reducing the proliferation, invasion, and migration of TNBC cells (2). Increased expression and leakage of lysosomal cathepsin D is associated with cardiomyocyte death related to hyperglycemia. Treatment with Pepstatin A markedly diminished high glucose-induced cardiomyocyte death (3). Pepstatin A treatment of osteoclast cells suppressed receptor activator of NF-κB ligand (RANKL)-induced differentiation to mononuclear osteoclast cells by blocking NFATc1 expression and inhibiting ERK signaling (4). Pepstatin A also inhibits human immunodeficiency virus (HIV) protease (5). Pepstatin A treatment of HIV-infected H9 cells decreased the level of HIV core antigen in the culture medium (6).
    For Research Use Only. Not For Use In Diagnostic Procedures.
    Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
    All other trademarks are the property of their respective owners. Visit our Trademark Information page.